Study record
Danazol reduces telomere attrition in telomere disease (Townsley et al., 2016)
Human clinical-outcome trial — disease population
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 2 — Human clinical-outcome RCT — disease population
Record
| Design | Prospective single-arm clinical trial (disease-outcome; telomere-attrition endpoint) |
| N | 27 |
| PMID | 27192671 |
| DOI | 10.1056/NEJMoa1515319 |
| Citation status | doi + PMID verified via Crossref 2026-07-12 (N Engl J Med 2016;374(20):1922-1931, Townsley et al., 'Danazol Treatment for Telomere Diseases'; PMID 27192671). NCT not separately fetched (DOI+PMID are the confirmed primary identifiers). |
Five-qualifier claim
| Species / population | 27 patients with telomere diseases (telomeropathy) and bone-marrow failure — a rare DISEASE population. |
| Exposure, route, schedule | Oral danazol 800 mg/day for up to 24 months. |
| Comparator / duration | Single-arm prospective trial with a pre-specified telomere-attrition endpoint; stopped early for efficacy. |
| Endpoint / numeric result | Telomere attrition was attenuated or reversed in ~92% of evaluable patients, with hematologic responses (improved blood counts) in the majority. |
| What it did NOT establish | Treatment of a rare genetic DISEASE, not healthy aging. No lifespan or general-population benefit is shown, and androgen toxicity limits broad use. |
Interventions
Primary reference
https://doi.org/10.1056/NEJMoa1515319
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.